Immunotherapy resistance is associated with poor T cell infiltration into tumors. Tumor-cell-intrinsic oncogenic events that contribute to this defect include Wnt–β-catenin activation. PAK4 is now identified as an upstream modulator of this pathway, thus suggesting the potential of enhancing the efficacy of immunotherapy by targeting this druggable kinase.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Neoadjuvant therapy-induced immune dynamics and myeloid-associated resistance in advanced head and neck cancer
npj Precision Oncology Open Access 07 June 2025
-
Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in GBM by reprogramming tumor microenvironment
Cell Death Discovery Open Access 03 April 2025
-
Engineered exosomes from different sources for cancer-targeted therapy
Signal Transduction and Targeted Therapy Open Access 15 March 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tumeh, P. C. et al. Nature 515, 568–571 (2014).
Ayers, M. et al. J. Clin. Invest. 127, 2930–2940 (2017).
Ribas, A. Cancer Discov. 5, 915–919 (2015).
Gajewski, T. F. et al. Curr. Opin. Immunol. 25, 268–276 (2013).
Spranger, S. & Gajewski, T. F. Nat. Rev. Cancer 18, 139–147 (2018).
Spranger, S., Bao, R. & Gajewski, T. F. Nature 523, 231–235 (2015).
Abril-Rodríguez, G. et al. Nat. Cancer https://doi.org/10.1038/s43018-019-0003-0 (2019).
Peng, W. et al. Cancer Discov. 6, 202–216 (2016).
Sweis, R. F. et al. Cancer Immunol. Res. 4, 563–568 (2016).
Skoulidis, F. et al. Cancer Discov. 8, 822–835 (2018).
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G. & Gajewski, T. F. Science 359, 1366–1370 (2018).
Chat, V. et al. Cancer Immunol. Immunother. 68, 897–905 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Gajewski, T.F., Fessler, J. PAK4 as a cancer immune-evasion target. Nat Cancer 1, 18–19 (2020). https://doi.org/10.1038/s43018-019-0012-z
Published:
Issue date:
DOI: https://doi.org/10.1038/s43018-019-0012-z
This article is cited by
-
Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in GBM by reprogramming tumor microenvironment
Cell Death Discovery (2025)
-
Neoadjuvant therapy-induced immune dynamics and myeloid-associated resistance in advanced head and neck cancer
npj Precision Oncology (2025)
-
Engineered exosomes from different sources for cancer-targeted therapy
Signal Transduction and Targeted Therapy (2023)
